Want to see PSNL full AI Analyst Report?
PSNL Stock Chart & Stats
$6.73
-$0.70(-11.71%)
At close: 4:00 PM EST
$6.73
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$3.84 - $16.39
Previous CloseN/A
Volume738.16K
Average Volume (3M)4.35M
Market Cap
$1.61B
Enterprise Value$469.27
Total Cash (Recent Filing)$233.22M
Total Debt (Recent Filing)$38.78M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 11, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding104,721,100
10 Day Avg. Volume6,043,678
30 Day Avg. Volume4,349,474
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-8.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.83Price Target Upside105.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$78.89M
Bulls Say, Bears Say
Bulls Say
Expanded Medicare ReimbursementExpanded CMS/MolDX coverage materially broadens access to Personalis' NeXT Personal assay across important oncology indications. Durable Medicare coverage tends to raise test ASPs, accelerate clinician adoption and referral patterns, and create a sustainable payer-backed revenue base that supports long‑term margin recovery as reimbursed volume scales.
Strong Liquidity And Low LeverageA sizable cash balance and low debt provide multi-quarter runway to invest in MRD commercialization, product development and payer engagement without immediate refinancing pressure. This financial flexibility reduces insolvency risk and enables strategic investments that can capture structural MRD market opportunities while reimbursement converts to higher-margin revenue.
Rapid Clinical Adoption And RetentionHigh test volume growth and extreme physician retention indicate strong product-market fit and recurring clinical demand. Durable clinician adoption and network effects improve the unit economics potential as scale increases, underpin ongoing commercial momentum and increase probability that reimbursed volumes and higher ASPs will follow over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow, with large planned cash usage, creates financing and dilution risk if reimbursement or margin recovery is delayed. Continued burn can erode the cash runway and force capital raises or spending cuts, constraining strategic execution and slowing the shift to profitable, reimbursed MRD volumes.
Severe Gross Margin CompressionDramatic margin collapse reflects a mix shift toward unreimbursed, low‑ASP tests while scaling claim submissions. Unit economics are currently impaired; meaningful and timely payer uptake is required to restore sustainable gross margins. Delays or adverse coverage decisions could prolong weak margins and necessitate further cash investment to subsidize scale.
Revenue Decline And Concentrated Mix RiskTop-line decline and reliance on a small set of large programs (e.g., prior Moderna-related revenue) highlight concentration and transition risk. Moving away from legacy/enterprise customers before reimbursed MRD volumes scale can depress revenue and worsen unit economics, making execution on biopharma MRD commercialization and payer coverage critical to stabilize durable growth.
Personalis News
PSNL FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was $3.84 and its highest was $16.39 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is $1.61B.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Aug 11, 2026 which is in 22 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on May 07, 2026. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.271 by -$0.019.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.26.
How many shares outstanding does Personalis have?
Personalis has 104,721,100 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.271. Following the earnings report the stock price went down -0.167%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.83 (105.55% Upside)
$13.83 (105.55% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 221.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 12.8%
Last 30 Days ▲ 12.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.06%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
PSNL Stock 12 Month Forecast
Average Price Target
$13.83
▲(105.55% Upside)
Technical Analysis
Ownership Overview
13.26% Insiders
11.58% Mutual Funds
50.41% Other Institutional Investors
10.14% Public Companies and
Individual Investors